[go: up one dir, main page]

EP1522857A1 - Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2 - Google Patents

Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2 Download PDF

Info

Publication number
EP1522857A1
EP1522857A1 EP03078161A EP03078161A EP1522857A1 EP 1522857 A1 EP1522857 A1 EP 1522857A1 EP 03078161 A EP03078161 A EP 03078161A EP 03078161 A EP03078161 A EP 03078161A EP 1522857 A1 EP1522857 A1 EP 1522857A1
Authority
EP
European Patent Office
Prior art keywords
galectin
rats
level
heart failure
cardiac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03078161A
Other languages
English (en)
French (fr)
Inventor
Yigat M. Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Maastricht
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Priority to EP03078161A priority Critical patent/EP1522857A1/de
Priority to PL04765681T priority patent/PL1682907T3/pl
Priority to EP04765681A priority patent/EP1682907B1/de
Priority to CN201210321227.7A priority patent/CN102998458B/zh
Priority to SI200431813T priority patent/SI1682907T1/sl
Priority to PCT/EP2004/010879 priority patent/WO2005040817A1/en
Priority to DK04765681.4T priority patent/DK1682907T3/da
Priority to JP2006530040A priority patent/JP4840744B2/ja
Priority to PL10186331T priority patent/PL2317324T3/pl
Priority to CA2542033A priority patent/CA2542033C/en
Priority to AU2004284496A priority patent/AU2004284496C1/en
Priority to PT101863314T priority patent/PT2317324E/pt
Priority to CN2004800332637A priority patent/CN1879022B/zh
Priority to AT04765681T priority patent/ATE532073T1/de
Priority to EP10186331.4A priority patent/EP2317324B1/de
Priority to PT04765681T priority patent/PT1682907E/pt
Priority to SI200432221T priority patent/SI2317324T1/sl
Priority to ES10186331T priority patent/ES2530567T3/es
Priority to ES04765681T priority patent/ES2377012T3/es
Priority to DK10186331.4T priority patent/DK2317324T3/en
Priority to CA2842308A priority patent/CA2842308A1/en
Priority to EP14192739.2A priority patent/EP2919012A1/de
Priority to US10/575,745 priority patent/US7888137B2/en
Publication of EP1522857A1 publication Critical patent/EP1522857A1/de
Priority to HK07106100.7A priority patent/HK1101426A1/xx
Priority to AU2009227844A priority patent/AU2009227844B2/en
Priority to JP2010167334A priority patent/JP2010279378A/ja
Priority to US12/914,329 priority patent/US8084276B2/en
Priority to JP2011088342A priority patent/JP5580774B2/ja
Priority to US13/304,145 priority patent/US20120220532A1/en
Priority to CY20121100108T priority patent/CY1112359T1/el
Priority to US13/791,350 priority patent/US20130189716A1/en
Priority to HK13111112.5A priority patent/HK1184534A1/zh
Priority to JP2014021394A priority patent/JP5789009B2/ja
Priority to US14/269,707 priority patent/US20150037353A1/en
Priority to CY20151100136T priority patent/CY1116147T1/el
Priority to JP2015081540A priority patent/JP2015171365A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9453—Cardioregulators, e.g. antihypotensives, antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Definitions

  • the present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as congestive heart failure.
  • HF Congestive heart failure
  • the object of the present invention is to provide a method by which patients can be identified who are at particular risk of developing hypertensive end organ damage, such as heart failure, or who are at particular risk to develop complications of heart failure. After identification, these patients may for example be treated before heart failure or its complications occur, which would be of great clinical importance.
  • the gene expression profile of a large number of genes from failing hypertophied hearts was compared with hypertrophied hearts that had remained compensated.
  • genes were identified that were differentially expressed in failing versus compensated hypertrophied hearts.
  • the present invention is based on the finding that particular non-myocytical genes are abnormally expressed in diseased heart tissue (Example 1 and 2).
  • non-myocytical markers that is, markers that are derived from cells other than cardiac myocytes.
  • This has the advantage that the method of the invention "probes" other processes than the known myoctic changes that occur in stressed myocytes. This opens the opportunity to not only diagnose heart failure, but also to continuously monitor patients with known heart failure, i.e. monitoring whether adverese non-myocytic processes (e.g. inflammation, scarring etc.) occur that may herald major adverse events.
  • adverese non-myocytic processes e.g. inflammation, scarring etc.
  • a biological sample is taken from an individual patient.
  • the level of one or more markers in said sample is measured by well-known techniques.
  • the level is compared with a standard level to determine whether the level of the marker is indicative of the potential of the individual to progress to heart failure.
  • the standard level is based on the level of said marker in healthy subjects. If the level of the marker is elevated compared to the standard level, the subject is at risk for developing CHF or developing complications of heart failure.
  • the biological sample may be any sample of body fluid, such as blood, plasma, serum, urine etc., or tissue sample such as a cardiac biopsy. According to a preferred embodiment of the invention, however, the biological sample is a plasma sample derived from peripheral blood. Peripheral blood samples can easily be taken from the patients and do not need complex invasive procedures such as catheterization. The biological sample may be processed according to well-known techniques to prepare the sample for testing.
  • the marker is a protein.
  • the level of proteins can easily be determined by simple and reliable methods, such as immunological methods using specific antibodies against the proteins.
  • the protein is galectin-3, as the level of galectin-3 has been demonstrated to be early and specifically expressed in failure-prone hearts.
  • the protein is thrombospondin-2. It has been demonstrated that increased cardiac expression of TSP2 identifies those hypertrophied hearts that are prone to progress to overt heart failure.
  • the level of the markers may be determined by a any well-known suitable method.
  • the level of the marker is measured by an enzyme-linked immunosorbent assay (ELISA), thus providing a simple, reproducible and reliable method.
  • ELISA enzyme-linked immunosorbent assay
  • the present invention further relates to the use of one or more non-myocytical markers for identifying a subject at risk of developing hypertensive end organ damage, such as congestive heart failure.
  • non-myocytical markers may be used according to the invention.
  • the marker is galectin-3, and/or thrombospondin-2.
  • the markers identified according to the present invention may further be used in the prevention and/or treatment of hypertensive end organ damage, in particular for the prevention and/or treatment of congestive heart failure.
  • inhibition of galectin-3 by for example antibodies, and/or activation of TSP-2 by suitable modulators may be beneficial for preventing the occurence of heart failure.
  • the present invention therefore further relates to the use of galectin-3 and/or modulators thereof for the manufacture of a medicament for the prevention and/or treatment of hypertensive end organ damage.
  • the invention further relates to the use of thrombospondin-2 and/or modulators thereof for the manufacture of a medicament for the prevention and/or treatment of hypertensive end organ damage.
  • Thrombospondin-2 increased expression identifies failure-prone cardiac hypertrophy
  • Cardiac hypertrophy increases the risk of heart failure (HF), but, so far, it has been is difficult to predict which hypertrophied myocardium will progress rapidly to HF. According to the present invention it was reasoned that, apart from hypertrophy-related genes, distinct failure-related genes are expressed before failure is apparent, thus permitting molecular prediction of hypertrophied hearts liable to fail.
  • Thrombospondin-2 (TSP2) was selectively overexpressed only in biopsies from rats that later progressed to HF, while brain natriuretic peptide (BNP) was, at this early stage, elevated in all rats.
  • TSP2 myocardial ,infarction
  • Ren-2 rats Homozygous Ren-2 rats were obtained from the Max-Delbrück-Zentrum für Molekulare Medizin, Berlin, Germany. 30 male Ren-2 rats on a Sprague Dawley (SD) background and 9 age-matched SD rats as controls were studied. Of 30 Ren-2 rats, 8 were sacrificed at 10-weeks of age and 8 were treated with 0.05 mg/kg/day of candesartan, an angiotensin II receptor type I blocker (ARB), from 7-13 weeks of age. Of the remaining 14 untreated Ren-2 rats, 6 were sacrificed at 13 weeks upon the development of clinical signs of heart failure and designated as HF-S rats. The remaining 8 Ren-2 rats were closely monitored and were sacrificed at 17 weeks when clinical signs of failure had not yet appeared. These rats were designated as HF-R rats. Hemodynamic parameters were determined before sacrifice and heart, lung and body weight were measured after the sacrifice. The procedure for care and treatment of animals was approved by the institutional animal care committee.
  • a second group of 12 Ren-2 and 4 SD rats were anesthetized and the anterior thorax was shaved at the sternum.
  • the rats were fixed to a hard board on top of a warming pad with the help of self-made loops.
  • a blunt 20-gauge needle was placed in the trachea to serve as a tracheal cannula.
  • the cannula was connected to a volume-cycled rodent respirator (model 683, Harvard Apparatus, South Natick, MA) on room air with a tidal volume of 2.5 to 3 ml and respiratory rate of 80 breaths/min. Further procedures were done with visual help of a micro-dissecting microscope.
  • a 5 mm incision at the left 4 th intercostal space was made to access the thorax. After having a clear view of the heart, a biopsy was taken using a custom-made 0.35 mm needle connected to a slowly rotating drill. The whole procedure lasted approximately 15 minutes. Of the 9 Ren-2 rats that survived the operation, 5 developed heart failure between 12-14 weeks of age whereas the remaining four rats stayed compensated until 17 weeks.
  • cDNA clones isolated from a normalized rat cDNA library were chosen for analysis on microarrays using an Incyte GEM-2/GEM-3 rat cDNA library (total 12,336 genes). PCR-amplified inserts of each cDNA were printed as high-density arrays on treated glass surfaces. Duplicate hybridizations were performed on these array elements with two SD and six Ren-2 rat myocardial mRNAs at 3 different time points. Log transformation of the values was done in order to homogenize the data, and only differences in expression of >1.7 fold were considered differentially expressed. The protocol for data mining and validation was adopted, as detailed previously (Tan et al., Proc Natl Acad Sci. 99: 11387-11392, 2002; Bandman et al., Ann NY Acad Sci., 975: 77-90, 2002).
  • Clones of the differentially expressed genes identified by microarray were obtained from Incyte genomics and sequenced with a 5'-GGTGACACTATAGAAGAGC-3'primer (Eurogentec, Seraing, Belgium). After confirming the identity by sequencing, the plasmid inserts were amplified by a PCR reaction with 5'-ACCATGATTACGCCAAGCTC-3' and 3'-ACGACGGCCAGTGAATTGAA-5' primers. Each clone was then spotted in duplicate on nylon membranes (macroarray). The dot blots were scanned with a personal fx-phospho imager (Cyclone System Packard, Meriden, CO, USA).
  • Glyceraldehyde-3-phosphate dehydrogenase was selected as a housekeeping gene for internal normalization of the blots.
  • Primers and probes were designed from rat sequences available in GenBankTM using Primer Express Software (PE Applied Biosystems, Foster City, CA, USA). Probes were designed from conserved exon splice sites derived from the Ensembl-Mouse Genome Sequencing Consortium and Ensembl-Human Genome Browser, thus preventing recognition by the assay of any potentially contaminating genomic DNA (Table 1). Optimal PCR conditions were found to be 12.5 ml 2x PCR Master Mix for TaqmanTM assays, with a final concentration of 5 mM MgCl 2 , 300 nM of each primer, 200 nM probe, and 10 ng cDNA-template in a total volume of 25 ml. Amplification and detection were carried out using the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). The PCR data were reported relative to the expression level of the housekeeping gene, cyclophilin A.
  • Myocardial infarction was induced in 22 wild-type (129 SvJ strain) and 16 TSP2- null mutant (TSP2 -/- ) mice by occluding the left anterior descending coronary artery. Two sham-operated mice were used as controls. These mice were killed, after ether anesthesia, by injecting 1 ml 0.1 M CdCl 2 into the vena cava. The heart was perfusion-fixed with 5% buffered formalin for 10 minutes and immersion-fixed overnight in 10% buffered formalin. Tissue specimens of wild-type and TSP2 -/- mice were evaluated using standard electron microscopical techniques.To quantify the extent of fibrosis, computerized planimetry was performed in seven randomly selected fields per section.
  • Collagen area was quantified selectively from left ventricular interstitium excluding perivascular and epicardial collagen. Collagen area fraction was calculated as the ratio of area stained by picrosirius-red to total myocardial area per field. The details of the procedure have been reported previously (Cherayil et al., Proc Natl Acad Sci USA, 87: 7324-7328, 1990; Cleutjens et al., Am J pathol., 147: 325-338, 1995).
  • Macroarray showed normalization of HF susceptibility genes by angiotensin II blockade
  • renin-angiotensin system RAS
  • ARB treatment prevented the overexpression of all HF-related candidate genes (data not shown).
  • TSP-2 knock out mice cannot survive acute myocardial infarction
  • TSP2 increases cardiac expression of TSP2 identifies those hypertrophied hearts that are prone to progress to overt heart failure. It was further shown that TSP2 is required to mount an effective response to acute cardiac loading. In contrast, known markers of hypertrophy like BNP were invariably increased in all forms of cardiac hypertrophy and therefore could not distinguish between failure-prone and failure-resistant forms of hypertrophy.
  • TSP2 may perform, directly or indirectly, a crucial function in cardiac matrix biology.
  • TSP2 is a secreted matricellular glycoprotein whose functions are diverse and incompletely understood. Since no close orthologues of TSP2 were found in the genomes of Caenorhabditis elegans or Drosophila, it appears that this protein has evolved to cope with the increased complexity of cell-matrix interaction in vertebrates. As evidence for a role of TSP2 in the organization of the extracellular matrix, previous studies in TSP2-null mice have shown that loss of TSP2 expression results in abnormally large collagen fibrils with irregular contours. Furthermore, the skin of TSP2- null mice is fragile and has reduced tensile strength.
  • TSP2-null skin fibroblasts are defective in their attachment to a substratum and have increased levels of matrix metalloproteinase-2 (MMP-2) in their culture.
  • MMP-2 matrix metalloproteinase-2
  • the current study has identified two, apparently contradictory, functions for TSP2 in the myocardium. In chronic hypertension in Ren-2 rats, increased cardiac expression of TSP2 identifies those animals that are prone to heart failure. While this response would appear to indicate that expression of TSP2 is detrimental, it is likely that the response reflects a heightened, previously activated , injury response in rats that later progress to overt failure, in comparison with the response in rats that remained compensated for a prolonged period of time. It is well established that the expression of TSP2 is characteristic of the response to injury in adult animals.
  • TSP2 functions as a crucial regulator of the integrity of the cardiac matrix. Since increased extracellular matrix formation characterizes both experimental and clinical forms of pressure overload-induced heart failure, the early expression of TSP2 may reflect a matrix response that is crucial in the transition from compensated hypertrophy to heart failure.
  • Ren-2 rats Homozygous Ren-2 rats were obtained from the Max-Delbruck-Zentrum für Molekulare Medizin, Berlin, Germany. We studied 16 male Ren-2 rats and 8 age-matched controls from the non-transgenic background, Sprague Dawley (SD) rats. Of the 16 Ren-2 rats, 8 were treated with 0.05 mg/kg/day of candesartan, an angiotensin II receptor type I blocker (ARB), from 7-13 weeks of age. Within 8 untreated Ren-2 rats, 4 were sacrificed at 13 weeks upon the development of HF. The remaining 4 Ren-2 rats were monitored and were sacrificed at 17 weeks when signs of clinical failure had not appeared. Hemodynamics was taken at 10 weeks and before sacrifice. Heart, lung and body weight were measured after the sacrifice. The procedure for care and treatment of animals was approved by the institutional animal care committee.
  • SD Sprague Dawley
  • a second group of 12 Ren-2 and 4 SD rats were anesthetized and a blunt 20-gauge needle was placed in the trachea to serve as a tracheal cannula, which was connected to a volume-cycled rodent respirator (model 683, Harvard Apparatus, South Natick, MA) on room air with a tidal volume of 2.5 to 3 ml and respiratory rate of 80 breaths/min.
  • a volume-cycled rodent respirator model 683, Harvard Apparatus, South Natick, MA
  • a 5 mm incision at the left 4 th intercostal space was made to access the thorax. Biopsy was taken using a custom-made 0.35 mm needle.
  • cDNA clones isolated from a normalized rat cDNA library were chosen for analysis on microarrays (Incyte Genomics, CA, USA, rat GEM-2/3). PCR amplified inserts of each cDNA were printed as high-density array on glass surfaces. Duplicate hybridizations were performed on these glass chips with two SD and six Ren-2 rat myocardial mRNA at three different time points. The target genes that showed statistically significant (P ⁇ 0.001) changes in expression with at least 2-fold overexpression in HF-S group were reprinted onto a sub-array for further analysis so that the genes were independently assessed four times to improve the level of reliability.
  • Clones of the differentially expressed genes identified by microarray were obtained from Incyte genomics and sequenced with 5'-GGTGACACTATAGAAGAGC-3'primer (Eurogentec, Seraing, Belgium). After confirming the identity, the plasmid inserts were amplified by PCR reaction with the 5'-ACCATGATTACGCCAAGCTC-3' and 3'-ACGACGGCCAGTGAATTGAA-5' primers. Each clone was then spotted in duplicates on nylon membrane (macroarray). The dot blots were scanned with the personal fx-phospho imager (Cyclone System Packard, Meriden, CO, USA).
  • Protein isolation and Western blotting was performed as described previously9.
  • Primary antibodies (Galectin-3, Bioreagents; ED-1 and OX-6, a kind gift from Dr. M. de Winther, Department of Molecular Genetics, University of Maastricht, The Netherlands) were diluted 1/1000 in tris-buffer saline with tween-20 (TBS-T).
  • Secondary antibody (horseradish-peroxidase conjugated IgG, Cell Signaling Technology) was diluted 1/2000 in TBS-T. Protein bands were visualized by enhanced chemiluminescence (ECL, Amersham, Arlington Heights, IL, USA) according to manufacturer's instructions.
  • galectin-3 and accessible binding sites were visualised by a specific anti-galectin-3 monoclonal antibody and biotinylated galectin-3, as described previously (Gabius et al., Anal Biochem.: 189: 91-94, 1990). As detailed elsewhere (Andre et al., Chembiochem. 2: 822-830, 2001) galectin-3 was biotinylated under activity-preserving conditions. In confocal laser scanning microscopy, galectin binding sites were detected by FITC-labelled avidin. A Texas-red labelled secondary antibody was used to visualise immunocytochemically the proliferating nuclear antigen (PCNA). Further details on the procedure are available elsewhere (Broers et al., J Cell Sci.: 112 (Pt 20): 3463-3475, 1999).
  • PCNA proliferating nuclear antigen
  • Rat cardiac fibroblasts were isolated from 2-day-old neonatal Sprague-Dawley rats, as described previously (Pokharel et al., Hypertension, 40: 155-161, 2002). Cells were cultured in Dulbecco's modification of eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS), along with 1% L-glutamate, 50 U/mL penicillin, and 0.1 g/L streptomycin, and were incubated at 37°C in a humidified 5% CO 2 atmosphere. Twenty-four hours after seeding, cells were made quiescent by incubation with media containing 0.5% FBS for 24 hours.
  • DMEM Dulbecco's modification of eagle's medium
  • FBS foetal bovine serum
  • Ren-2 rats had LVH but no haemodynamic evidence for decompensation (LV weight/body weight %: Ren-2, 3.88 ⁇ 0.08 vs non-transgenic controls 2.15 ⁇ 0.2, and dP/dt max : Ren-2, 8556 ⁇ 296 vs non-transgenic controls 8780 ⁇ 373).
  • Myocardial collagen content determined by computer-assisted densitometry, revealed higher degree of cardiac fibrosis in the HF-S rats compared to HF-R rats. ARB normalized LVH and myocardial collagen content so that it remained comparable to that of the normotensive background strains (figure 7).
  • Microarray reveals abundance of immune-related genes in HF susceptible rats
  • Macroarray reveals normalization of HF susceptibility genes by angiotensin II blockade
  • galectin-3 binds to cardiac fibroblasts.
  • galectin-3 binding sites In 0.1% Triton-permeabilised cells, presence of galectin-3 binding sites resulted in diffuse cytoplasmic as well as perinuclear staining in resting cells ( Figure 10 a).
  • proliferating fibroblasts showed enhanced staining around the nucleus, revealing a mitosis-related alteration in staining profile ( Figure 10 b). This pattern was independently monitored by confocal microscopy.
  • Galectin-3 induced fibroblast proliferation and collagen production
  • galectin-3 stimulates the growth of cardiac fibroblasts.
  • galectin-3 was added in different concentrations (0, 10 and 30 ⁇ g/ml) with and without serum enrichment.
  • cpm counts per minute
  • galectin-3 at 10 ⁇ g/ml 309 ⁇ 4.8 cpm; control, 145 ⁇ 4.8; p ⁇ 0.01).
  • galectin-3 a macrophage expressed protein
  • galectin-3 binds to intracellular binding sites in cardiac fibroblasts and activates cardiac fibroblast proliferation and collagen production, suggesting that this can contribute to myocardial stiffness and probably progression towards HF.
  • galectin-3 is the only chimera-type member of the galectin family. It has a lectin group sharing calcium-independent specificity to ⁇ -galactosides as well as proteins and is located in the phagocytic cups and phagosomes of the macrophages. Besides its anti-apoptotic and growth promoting actions, galectin-3 also regulates monocyte chemotaxis, chemokinesis and modulates the availability of cytokines. Furthermore, recent studies have also suggested that galectin-3 plays a critical role in phagocytosis by macrophages when cross-linked by Fc ⁇ receptor (Fc ⁇ R).
  • Fc ⁇ R Fc ⁇ receptor
  • galectin-3 expressed by liver-analogues of macrophages (i.e., kupffer cells), have been implicated to induce the synthesis of excess fibril-forming collagens in liver. This suggests that galectin-3 is a macrophage related pro-fibrotic mediator and yet another inflammatory infiltrate cytokine with the potential to influence cardiac remodeling in conditions charaterized by macrophage infiltration.
  • galectin-3 as the third receptor for advanced glycosylation end-products (RAGE-3), that have critical role in collagen cross-linking and myocardial stiffness.
  • galectin-3 binds to intracellular receptors and induces cardiac fibroblast proliferation and accentuates collagen production.
  • galectin-3 is known to specifically interact with intracellular targets besides glycoconjugates.
  • Previous studies have proposed several molecules as galectin-3 binding sites including, Mac-2 binding protein, and laminin.
  • the current study suggests a key role for immune system activation and galectin-3 production in the progression from left ventricular hypertrophy to HF and demonstrates a link between pro-immune and pro-fibrotic factors.
  • the increased expression of galectin-3 preceding HF can reflect the early and aberrant activation of macrophages in hypertrophied failing ventricles.
  • Galectin-3 in turn, can relay signals from activated macrophages to cardiac fibroblasts.
  • Peripheral detection of galectin-3 can serve as a predictor of HF and therapeutic inhibition of galectin-3 action can become a novel therapeutic target to counteract excess cardiac fibrosis.
  • Galectin-3 levels were measured in the serum of patients with cardiovascular disease.
  • a commercially available kit to measure galectin-3 by ELISA was employed. The results are summarized in Table 4-6. It was shown that Galectin-3 is significantly elevated in the serum of patients with cardiovascular disease such as heart failure, LVH. Moreover, an upper limit for galectin-3 levels in healthy control subjects was found, which is surpassed in most CHF patients.
  • the probes were labelled at the 5' and 3' positions with 6-carboxyfluorescein reporter and 6-carboxytetramethylrhodamine quencher, respectively.
  • the position of the primers and probes were annotated according to the sequences derived from GenBank (accession numbers given in parenthesis). Fwd, forward; Rev, reverse.
  • the probes were labelled at the 5' and 3' positions with 6-carboxyfluorescein reporter and 6-carboxytetramethylrhodamine quencher, respectively.
  • the position of the primers and probes were annotated according to the sequences derived from GenBank (accession numbers given in parenthesis). Fwd, forward; Rev, reverse.
  • Galectin-3 descriptives 95% Confidence Interval for Mean N Mean Std. Deviation Std. Error Lower Bound Upper Bound Minimum Maximum LVH 22 6,253 1,457 ,311 5,607 6,899 3,7 8,8 chf 39 9,392 1,845 ,295 8,794 9,990 5,0 13,1 infl 15 7,427 1,678 ,433 6,498 8,356 4,6 10,5 poscon 3 6,660 ,871 ,503 4,496 8,824 5,9 7,6 infarct 6 6,317 1,262 ,515 4,992 7,641 5,3 8,5 healthy 26 4,717 1,125 ,221 4,262 5,171 2,8 6,8 Total 111 7,169 2,390 ,227 6,720 7,619 2,8 13,1 ANOVA Sum of Squares df Mean Square F Sig.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
EP03078161A 2003-10-09 2003-10-09 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2 Withdrawn EP1522857A1 (de)

Priority Applications (36)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (de) 2003-10-09 2003-10-09 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
ES10186331T ES2530567T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
DK10186331.4T DK2317324T3 (en) 2003-10-09 2004-09-27 A method of identifying an individual at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
CN201210321227.7A CN102998458B (zh) 2003-10-09 2004-09-27 通过测定半乳糖苷凝集素-3或者血小板反应蛋白-2的水平鉴定具有发生心力衰竭风险的受试者的方法
SI200431813T SI1682907T1 (sl) 2003-10-09 2004-09-27 Postopek identifikacije subjekta ki mu grozi nevarnost srčne odpovedi z ugotavljanjem nivoja galaktina ali trombospondina
PCT/EP2004/010879 WO2005040817A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
EP14192739.2A EP2919012A1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
JP2006530040A JP4840744B2 (ja) 2003-10-09 2004-09-27 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
PL10186331T PL2317324T3 (pl) 2003-10-09 2004-09-27 Sposób identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2
CA2542033A CA2542033C (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2004284496A AU2004284496C1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
PT101863314T PT2317324E (pt) 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2
CN2004800332637A CN1879022B (zh) 2003-10-09 2004-09-27 通过测定半乳糖苷凝集素-3或者血小板反应蛋白-2的水平鉴定具有发生心力衰竭风险的受试者的方法
AT04765681T ATE532073T1 (de) 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
EP10186331.4A EP2317324B1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
PT04765681T PT1682907E (pt) 2003-10-09 2004-09-27 Método para identificar um indivíduo em risco de desenvolver insuficiência cardíaca pela determinação do nível de galectina-3 ou trombospondina-2
SI200432221T SI2317324T1 (sl) 2003-10-09 2004-09-27 Postopek identifikacije subjekta, ki mu grozi nevarnost srčne odpovedi z ugotavljanjem nivoja galektina-3 ali trombospondina-2
PL04765681T PL1682907T3 (pl) 2003-10-09 2004-09-27 Metoda identyfikacji podmiotu objętego ryzykiem rozwinięcia niewydolności serca poprzez określenie poziomu galektyny-3 lub trombospondyny-2
ES04765681T ES2377012T3 (es) 2003-10-09 2004-09-27 Método para identificar un sujeto susceptible de desarrollar insuficiencia cardíaca determinando el nivel de galectina-3 o trombospondina-2
CA2842308A CA2842308A1 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of thrombospondin-2
EP04765681A EP1682907B1 (de) 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
DK04765681.4T DK1682907T3 (da) 2003-10-09 2004-09-27 Fremgangsmåde til identificering af en person med risiko for udvikling af hjerteinsufficiens ved hjælp af bestemmelse af niveauet af galectin-3 eller thrombospondin-2
US10/575,745 US7888137B2 (en) 2003-10-09 2004-09-27 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
HK07106100.7A HK1101426A1 (en) 2003-10-09 2007-06-07 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
AU2009227844A AU2009227844B2 (en) 2003-10-09 2009-10-19 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
JP2010167334A JP2010279378A (ja) 2003-10-09 2010-07-26 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
US12/914,329 US8084276B2 (en) 2003-10-09 2010-10-28 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
JP2011088342A JP5580774B2 (ja) 2003-10-09 2011-04-12 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
US13/304,145 US20120220532A1 (en) 2003-10-09 2011-11-23 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
CY20121100108T CY1112359T1 (el) 2003-10-09 2012-02-01 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2
US13/791,350 US20130189716A1 (en) 2003-10-09 2013-03-08 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
HK13111112.5A HK1184534A1 (zh) 2003-10-09 2013-09-27 通過測定半乳糖苷凝集素- 或者血小板反應蛋白- 的水平鑒定具有發生心力衰竭風險的受試者的方法
JP2014021394A JP5789009B2 (ja) 2003-10-09 2014-02-06 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法
US14/269,707 US20150037353A1 (en) 2003-10-09 2014-05-05 Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
CY20151100136T CY1116147T1 (el) 2003-10-09 2015-02-12 Μεθοδος για την ταυτοποιηση ενος υποκειμενου που κινδυνευει να παρουσιασει καρδιακη ανεπαρκεια, μεσω του προσδιορισμου του επιπεδου γαλεκτινης-3 ή θρομβοσπονδινης-2
JP2015081540A JP2015171365A (ja) 2003-10-09 2015-04-13 ガレクチン−３またはトロンボスポンジン−２のレベルを定量することによって心不全を発症する危険性がある対象を同定する方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078161A EP1522857A1 (de) 2003-10-09 2003-10-09 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2

Publications (1)

Publication Number Publication Date
EP1522857A1 true EP1522857A1 (de) 2005-04-13

Family

ID=34306912

Family Applications (4)

Application Number Title Priority Date Filing Date
EP03078161A Withdrawn EP1522857A1 (de) 2003-10-09 2003-10-09 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
EP04765681A Expired - Lifetime EP1682907B1 (de) 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
EP14192739.2A Withdrawn EP2919012A1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
EP10186331.4A Expired - Lifetime EP2317324B1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2

Family Applications After (3)

Application Number Title Priority Date Filing Date
EP04765681A Expired - Lifetime EP1682907B1 (de) 2003-10-09 2004-09-27 Verfahren zur identifizierung einer untersuchungsperson in gefahr, an herzversagen zu erkranken, durch bestimmung des galectin-3- oder thrombospondin-2-spiegels
EP14192739.2A Withdrawn EP2919012A1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
EP10186331.4A Expired - Lifetime EP2317324B1 (de) 2003-10-09 2004-09-27 Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2

Country Status (15)

Country Link
US (5) US7888137B2 (de)
EP (4) EP1522857A1 (de)
JP (5) JP4840744B2 (de)
CN (2) CN102998458B (de)
AT (1) ATE532073T1 (de)
AU (2) AU2004284496C1 (de)
CA (2) CA2542033C (de)
CY (2) CY1112359T1 (de)
DK (2) DK1682907T3 (de)
ES (2) ES2377012T3 (de)
HK (2) HK1101426A1 (de)
PL (2) PL2317324T3 (de)
PT (2) PT1682907E (de)
SI (2) SI1682907T1 (de)
WO (1) WO2005040817A1 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008037720A2 (en) * 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
EP2109688A2 (de) * 2007-01-23 2009-10-21 University Of Virginia Patent Foundation Galectin-3 bindendes protein als biomarker für herz-kreislauf-erkrankungen
WO2010096126A1 (en) * 2008-10-29 2010-08-26 Bg Medicine, Inc. Galectin-3 immunoassay
EP2460890A1 (de) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) GPNMB/Osteoactivin als Arzneimitteltarget und Biomarker bei Herzerkrankungen
US8703433B2 (en) * 2010-10-18 2014-04-22 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
US20110046187A1 (en) * 2007-09-17 2011-02-24 Bg Medicine, Inc. Assessing congestive heart risk in patients treated or potentially to be treated with a peroxisome-proliferator-activator-receptor-gamma agonist or a thiazolidinedione
JP5702386B2 (ja) * 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法
WO2012003475A1 (en) 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
CA2825954A1 (en) * 2011-01-31 2012-08-09 Bg Medicine, Inc. Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN104011544B (zh) * 2011-12-08 2018-06-05 艾莱兹疗法股份有限公司 通过血浆去除术降低半乳凝素-3的水平
ES2742291T3 (es) * 2012-09-27 2020-02-13 Siemens Healthcare Diagnostics Inc Cistatina C y Galectina-3 como biomarcadores para la hipertensión arterial pulmonar
CA2926480A1 (en) * 2012-11-15 2014-05-22 Tufts University Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
AU2016207734A1 (en) 2015-01-18 2017-08-03 Diasorin S.P.A. Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker
US10688565B2 (en) * 2015-05-28 2020-06-23 Kyocera Corporation Cutting tool
CN112553335A (zh) * 2020-12-17 2021-03-26 核工业总医院 肾细胞癌生物标志物及其应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
EP0988552B1 (de) 1997-06-10 2010-11-24 Lpath, Inc. Verfahren zum frühzeitigen nachweis herzerkrankungen
US20060166276A1 (en) * 1997-09-05 2006-07-27 Lung Health Diagnostics Pty Ltd Method of diagnosis and agents useful for same
DE69841804D1 (de) * 1997-09-05 2010-09-16 Southern Medical Diagnostics P Diagnoseverfahren
CA2306751C (en) * 1997-10-24 2006-12-12 Shionogi & Co., Ltd. Method for inhibiting degradation of natriuretic peptides and improved method for measuring natgriuretic peptides with the use of the same
DE69932235T2 (de) * 1998-04-02 2007-06-14 Genentech, Inc., South San Francisco Behandlung von herzhypertrophie
DK1151304T3 (da) * 1999-01-29 2008-01-28 Roche Diagnostics Gmbh Fremgangsmåde til påvisning af N-terminalt proBNP
JP2003506016A (ja) * 1999-02-19 2003-02-18 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 動脈壁破裂障害のための診断剤および治療剤
EP1210453B1 (de) * 1999-08-20 2009-02-11 Board Of Regents, The University Of Texas System Hdac4- und hdac5-abhängige regulation der genexpression im herzen
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
EP1358347A2 (de) 2000-04-05 2003-11-05 Incyte Genomics, Inc. Gene, die während der schaumzelldifferenzierung exprimiert werden
KR100395254B1 (ko) * 2000-10-30 2003-08-21 (주)자리타 바이오텍 종양 발생 예측 키트
AU2002220266A1 (en) * 2000-11-09 2002-05-21 Millennium Pharmaceuticals, Inc. Methods for the identification and the treatment of cardiovascular disease
US7432060B2 (en) * 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
WO2002046475A2 (en) * 2000-12-08 2002-06-13 Curagen Corporation Method of detecting and treating tuberous sclerosis complex associated disorders
JP4035562B2 (ja) * 2001-01-31 2008-01-23 国立大学法人富山大学 ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
CA2441086A1 (en) * 2001-03-19 2002-09-26 Wisconsin Alumni Research Foundation Identification of gene expression alterations underlying the aging process in mammals
US20060019235A1 (en) * 2001-07-02 2006-01-26 The Board Of Trustees Of The Leland Stanford Junior University Molecular and functional profiling using a cellular microarray
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20030099958A1 (en) * 2001-09-05 2003-05-29 Vitivity, Inc. Diagnosis and treatment of vascular disease
GB0124145D0 (en) 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
US20060141493A1 (en) * 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
DE60323091D1 (de) * 2002-05-13 2008-10-02 Arexis Ab Autoimmunerkrankungen und nadph-oxidase-defekte
WO2004038376A2 (en) 2002-10-24 2004-05-06 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
BR0316111A (pt) * 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
EP1431399A1 (de) * 2002-12-20 2004-06-23 Clinigenetics Verfahren und Zusammen setzung zur Identifizierung von therapeutischen Mitteln gegen atheriosklerotische Plaques
US6889083B2 (en) 2003-04-21 2005-05-03 Medtronic, Inc. Atrial tracking recovery to restore cardiac resynchronization therapy in dual chamber tracking modes
US20070105105A1 (en) * 2003-05-23 2007-05-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2004111654A2 (en) 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
EP1522857A1 (de) * 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
DE10347436B4 (de) 2003-10-13 2007-08-02 Johann Wolfgang Goethe-Universität Frankfurt am Main In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
EP1720562A4 (de) * 2004-01-15 2009-10-28 Scios Inc Verfahren zur behandlung von kardialer remodellierung nach myokardschädigung
WO2006026074A2 (en) 2004-08-04 2006-03-09 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
US20090258002A1 (en) 2005-02-01 2009-10-15 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for Tissue Status
US20070092886A1 (en) * 2005-03-22 2007-04-26 Raymond Tabibiazar Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
US7632634B2 (en) * 2005-04-15 2009-12-15 University Of Maryland Biotechnology Institute Method and assay for early diagnosis of prostate cancer
US9592970B2 (en) 2008-07-17 2017-03-14 Toby D. Henderson Robotic gantry with end effector for product lifting
CN104198712A (zh) 2008-10-29 2014-12-10 Bg医药股份有限公司 半乳凝素-3免疫测定法
JP5702386B2 (ja) 2009-08-25 2015-04-15 ビージー メディシン， インコーポレイテッド ガレクチン−３および心臓再同期療法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CLEUTJENS JACK P M ET AL: "Thrombospondin 2 deficiency in mice results in cardiac rupture early after myocardial infarction", CIRCULATION, vol. 100, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.56, XP009027984, ISSN: 0009-7322 *
GIORDANENGO L ET AL: "Anti-galectin-1 autoantibodies in human Trypanosoma cruzi infection: Differential expression of this beta-galactoside-binding protein in cardiac Chagas' disease", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 124, no. 2, May 2001 (2001-05-01), pages 266 - 273, XP009028059, ISSN: 0009-9104 *
MATTHEWS KENNETH P ET AL: "Evidence for IgG autoantibodies to galectin-3, a beta-galactoside-binding lectin (Mac-2, epsilon binding protein, or carbohydrate binding protein 35) in human serum", JOURNAL OF CLINICAL IMMUNOLOGY, vol. 15, no. 6, 1995, pages 329 - 337, XP009027994, ISSN: 0271-9142 *
SCHROEN BLANCHE ET AL: "Genomic analysis identifies thrombospondin-2 as a molecular predictor of heart failure.", CIRCULATION, vol. 108, no. 17 Supplement, 28 October 2003 (2003-10-28), American Heart Association Scientific Sessions 2003;Orlando, FL, USA; November 09-12, 2003, pages IV - 260, XP009027986, ISSN: 0009-7322 (ISSN print) *
SHARMA UMESH C ET AL: "Galectin-3 is a novel macrophage derived mediator of cardiac fibrosis and specifically marks failing hearts.", CIRCULATION, vol. 108, no. 17 Supplement, 28 October 2003 (2003-10-28), American Heart Association Scientific Sessions 2003;Orlando, FL, USA; November 09-12, 2003, pages IV - 261, XP009027985, ISSN: 0009-7322 (ISSN print) *
SHIRAKATA Y ET AL: "Inverse regulation of the angiogenesis factor VEGF and the angiogenesis inhibitors thrombospondin-1 and TSP-2 in human epidermal keratinocytes", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 117, no. 2, August 2001 (2001-08-01), 62nd Annual Meeting of the Society for Investigative Dermatology;Washington, DC, USA; May 09-12, 2001, pages 391, XP001180423, ISSN: 0022-202X *
TOPOL ERIC J ET AL: "Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction", CIRCULATION, vol. 104, no. 22, 27 November 2001 (2001-11-27), pages 2641 - 2644, XP001180429, ISSN: 0009-7322 *
WALTON BRIAN ET AL: "Thrombospondin-2 and lymphotoxin-alpha gene variations predict coronary heart disease in a large prospective study.", CIRCULATION, vol. 108, no. 17 Supplement, 28 October 2003 (2003-10-28), American Heart Association Scientific Sessions 2003;Orlando, FL, USA; November 09-12, 2003, pages IV - 771, XP009027983, ISSN: 0009-7322 (ISSN print) *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2434287A1 (de) * 2006-09-25 2012-03-28 Universiteit Maastricht Mittel und Verfahren zur Diagnose und/oder Behandlung eines Patienten in Gefahr, an Herzversagen zu erkranken
WO2008037720A3 (en) * 2006-09-25 2009-04-09 Univ Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
AU2012216816B2 (en) * 2006-09-25 2014-05-29 Universiteit Maastricht Means and methods for diagnosing and/ or treating a subject at risk of developing heart failure
WO2008037720A2 (en) * 2006-09-25 2008-04-03 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US8153376B2 (en) 2006-09-25 2012-04-10 Universiteit Maastricht Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
EP2434288A1 (de) * 2006-09-25 2012-03-28 Universiteit Maastricht Mittel und Verfahren zur Diagnose und/oder Behandlung eines Patienten mit Gefahr der Entwicklung von Herzversagen
EP2109688A4 (de) * 2007-01-23 2010-02-17 Univ Virginia Galectin-3 bindendes protein als biomarker für herz-kreislauf-erkrankungen
EP2109688A2 (de) * 2007-01-23 2009-10-21 University Of Virginia Patent Foundation Galectin-3 bindendes protein als biomarker für herz-kreislauf-erkrankungen
KR20110104930A (ko) * 2008-10-29 2011-09-23 비쥐 메디신, 인코포레이티드 갈렉틴-３ 면역검정
WO2010096126A1 (en) * 2008-10-29 2010-08-26 Bg Medicine, Inc. Galectin-3 immunoassay
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
CN102257390B (zh) * 2008-10-29 2015-04-01 Bg医药股份有限公司 半乳凝素-3免疫测定法
US8703433B2 (en) * 2010-10-18 2014-04-22 Hideaki Hara Marker for amyotrophic lateral sclerosis, and use thereof
EP2460890A1 (de) * 2010-12-01 2012-06-06 Max-Delbrück-Centrum für Molekulare Medizin (MDC) GPNMB/Osteoactivin als Arzneimitteltarget und Biomarker bei Herzerkrankungen
WO2012072752A1 (en) 2010-12-01 2012-06-07 Max-Delbrück-Centrum Für Molekulare Medizin Berlin-Buch Gpnmb/osteoactivin as a biomarker and drug target in cardiac diseases

Also Published As

Publication number Publication date
DK1682907T3 (da) 2012-08-13
CA2542033C (en) 2014-04-29
PL1682907T3 (pl) 2012-03-30
JP5789009B2 (ja) 2015-10-07
CA2542033A1 (en) 2005-05-06
SI2317324T1 (sl) 2015-11-30
CN1879022B (zh) 2012-10-17
JP2015171365A (ja) 2015-10-01
AU2004284496B2 (en) 2009-08-06
CA2842308A1 (en) 2005-05-06
US8084276B2 (en) 2011-12-27
EP2919012A1 (de) 2015-09-16
WO2005040817A1 (en) 2005-05-06
JP5580774B2 (ja) 2014-08-27
US20110104722A1 (en) 2011-05-05
EP2317324B1 (de) 2014-11-12
CY1116147T1 (el) 2017-02-08
PL2317324T3 (pl) 2015-10-30
DK2317324T3 (en) 2015-02-16
US20080193954A1 (en) 2008-08-14
PT2317324E (pt) 2015-02-17
US20130189716A1 (en) 2013-07-25
US7888137B2 (en) 2011-02-15
CN1879022A (zh) 2006-12-13
HK1184534A1 (zh) 2014-01-24
AU2009227844B2 (en) 2012-07-19
JP2014115297A (ja) 2014-06-26
ES2530567T3 (es) 2015-03-03
CN102998458B (zh) 2015-07-22
ATE532073T1 (de) 2011-11-15
ES2377012T3 (es) 2012-03-21
JP2007508527A (ja) 2007-04-05
JP2010279378A (ja) 2010-12-16
SI1682907T1 (sl) 2012-03-30
EP2317324A1 (de) 2011-05-04
JP2011177184A (ja) 2011-09-15
AU2004284496C1 (en) 2010-03-04
JP4840744B2 (ja) 2011-12-21
CN102998458A (zh) 2013-03-27
US20150037353A1 (en) 2015-02-05
US20120220532A1 (en) 2012-08-30
EP1682907A1 (de) 2006-07-26
CY1112359T1 (el) 2015-12-09
AU2009227844A1 (en) 2009-11-26
EP1682907B1 (de) 2011-11-02
AU2004284496A1 (en) 2005-05-06
PT1682907E (pt) 2012-02-03
HK1101426A1 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
US8084276B2 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US9518992B2 (en) Kits for the diagnosis of pre-eclampsia or eclampsia
US20050287565A1 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
AU2012244071B2 (en) Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US7524636B2 (en) Methods for diagnosing labor
US20030036103A1 (en) Methods and compositions for diagnosis and treatment of vascular conditions
US20080207671A1 (en) Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
JP6065172B2 (ja) 微小血管障害又はその関連疾患のバイオマーカー

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

AKX Designation fees paid
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051014